LEARNING OBJECTIVES

• Understanding treatment options in the management of frontline CLL and how to approach patient selection
• Integrate the emerging data into clinical practice when providing treatment options to patients in the management of relapsed CLL and how to sequence therapies
• Share experience and gain knowledge on best practices of effective management of adverse events associated with treatment options

WEDNESDAY, APRIL 25, 2018

MUHC- GLEN
08:30 to 09:30
Block D, Room D.02.1312
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

HOPITAL CHARLES LEMOYNE
12:00-13:00
Local HN-106 at CICM

THURSDAY, APRIL 26, 2018

JEWSIH GENERAL HOSPITAL
12:30 to 13:30
Room E-711

SACRE COEUR HOSPITAL
15:00 to 16:00
Room G-4130

Refreshments will be served at each location.
To organize a videconference: vspo@mcgill.ca

LEARNING OBJECTIVES

• Understanding treatment options in the management of frontline CLL and how to approach patient selection
• Integrate the emerging data into clinical practice when providing treatment options to patients in the management of relapsed CLL and how to sequence therapies
• Share experience and gain knowledge on best practices of effective management of adverse events associated with treatment options

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Shire